A phase 1, open-label, dose-escalation clinical study to assess the safety and tolerability of MS-R001 [sirolimus] in patients with diabetic macular edema secondary to diabetic retinopathy.

Trial Profile

A phase 1, open-label, dose-escalation clinical study to assess the safety and tolerability of MS-R001 [sirolimus] in patients with diabetic macular edema secondary to diabetic retinopathy.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2012

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jan 2012 Results published in Ophthalmology.
    • 23 Jul 2010 Santen Pharmaceutical added as trial sponsor and lead trial centre as reported by ClinicalTrials.gov.
    • 17 Jul 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top